Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Tran

Showing results (121-130 of 170) with videos related to

Pageof 17
Sort By:
European Urology|October 8, 2025
Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 StudySiamak Daneshmand, Renata Zaucha, James W F Catto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyLavinia Tan, Ben Tran, Jeanne Tie, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Asia-Pacific Journal of Clinical Oncology|January 24, 2022
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancerChia Yuen Chong, Azim Jalali, Hui Li Wong, et al.
World Journal of Urology|October 2, 2021
A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissectionsPaul Lloyd, Anne Hong, Marc A Furrer, et al.
Prostate Cancer and Prostatic Diseases|June 10, 2021
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancerPatrick McCoy, Stefano Mangiola, Geoff Macintyre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2016
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon CancerPradipta Ghosh, Jeanne Tie, Andrea Muranyi, et al.
Nature Communications|July 8, 2026
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinomaVan To, Niko Thio, Rebecca Castle, et al.
European Urology|September 8, 2021
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical TrialEdmond M Kwan, Lavinia Spain, Angelyn Anton, et al.
Pageof 17

Showing results (121-130 of 170) with videos related to

Sort By:
Pageof 17
European Urology|October 8, 2025
Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 StudySiamak Daneshmand, Renata Zaucha, James W F Catto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyLavinia Tan, Ben Tran, Jeanne Tie, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Asia-Pacific Journal of Clinical Oncology|January 24, 2022
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancerChia Yuen Chong, Azim Jalali, Hui Li Wong, et al.
World Journal of Urology|October 2, 2021
A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissectionsPaul Lloyd, Anne Hong, Marc A Furrer, et al.
Prostate Cancer and Prostatic Diseases|June 10, 2021
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancerPatrick McCoy, Stefano Mangiola, Geoff Macintyre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2016
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon CancerPradipta Ghosh, Jeanne Tie, Andrea Muranyi, et al.
Nature Communications|July 8, 2026
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinomaVan To, Niko Thio, Rebecca Castle, et al.
European Urology|September 8, 2021
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical TrialEdmond M Kwan, Lavinia Spain, Angelyn Anton, et al.
Pageof 17